RESUMEN
Background: Fibroblast growth factor 23 (FGF23) is a phosphate-regulating hormone primarily secreted by osteocytes. Levels of FGF23 increase as kidney function declines as a physiologic response to maintain normal serum phosphate levels and neutral phosphate balance. Although FGF23 helps to prevent hyperphosphatemia, elevated circulating levels are independently associated with vascular dysfunction, left ventricular hypertrophy, increased risk for ESRD, and death in patients with CKD. Aim of the study: To evaluate the FGF23 and eGFR levels in chronic kidney disease patients to compare them with healthy controls. Materials and methods: Totally 100 patients were included in the study. The study was conducted from June 2018 – November 2018 over a period of 6 months at Nephrology department of DSMCH, Perambalur. Group – I (50) who were in CKD stage - IV. Group - II (50) healthy controls were included in the study. Fibroblast growth factor 23 (FGF23) was estimated by standard techniques and results are analyzed accordingly. Results: The mean value of FGF23 in Group – I was 730.7 ± 492.72 pg/ml was higher than that of the Group – II whose mean value was 39.49 ± 12.47 pg/ml and this difference was statistically significant( p<0.05). Group – I had very low mean eGFR levels than Group - II and this difference was statistically significant. Conclusion: Higher FGF23 levels are independently associated with higher levels of inflammatory markers in patients with CKD and with significantly greater odds of severe inflammation. Future studies should evaluate whether inflammation modifies the association between FGF23 and adverse outcomes in CKD.
RESUMEN
Background: Hypothyroidism is the most common pregnancy-related thyroid disorder, affecting 3– 5% of all pregnant women. Pregnant women are often iron deficient, and iron deficiency has adverse effects on thyroid metabolism. Impaired maternal thyroid function during pregnancy may cause neurodevelopmental delays in the offspring. Iron deficiency is frequent during the first trimester of pregnancy and associated with a higher prevalence of thyroid autoimmunity, higher serum TSH and lower fT4 levels. Anemia is a decrease in the number of red blood cells (RBC's) or less than the normal quantity of hemoglobin in the blood. Anemia can have several reasons, such as abnormality of the formation and reduction on the half-life of the red cells. Aim of the study: To evaluate the thyroid status in second-trimester antenatal cases. Materials and methods: Totally 60 female patients were included in the study. Group-1(30) pregnant women with hypothyroidism. Group -2(30) pregnant women without hypothyroidism. The study was conducted from July – November 2018 over a period of 6 months at OG Department of DSMCH, perambalur. Ferritin levels were estimated in 60 female patients newly diagnosed patients of hypothyroidism using chemiluminescence technique (advia centaur cp). Total T3 and T4 levels were estimated using radioimmunoassay. Free T3, T4, and thyroid-stimulating hormone (TSH) levels were estimated using chemiluminescence. These were then compared with age- and sex-matched healthy controls. Results were correlated statistically. Results: Serum ferritin levels were found to be significantly reduced in pregnant women with hypothyroidism compared to normal pregnant women (p < 0.001). Conclusion: Complications that may occur during pregnancy and delivery could be due to low thyroid function, but was not able to be clearly proven in this study. Although prior or early- Nageshwari A, G. Kavitha. To evaluate the influence of ferritin on thyroid hormones in second trimester antenatal cases in Perambalur District. IAIM, 2019; 6(1): 30-34. Page 31 pregnancy testing for iodine level and thyroid function can help early identify iodine deficiency and thyroid disorder, justifying a general screening will require further studies with multicentrerecruitment and ante-natal clinics involvement